Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

EL5-Energo reported for 3 months of 2025 by IFRS

4/29/25 ELFV

Board of Directors of Arsagera recommended that dividends be paid for 2024

4/29/25 ARSA

Novatek reports for 3 months of 2025 by RAS

4/29/25 NVTK

Cherkizovo reports for 3 months of 2025 by RAS

4/29/25 GCHE

RSC Energia reported for 3 months of 2025 by RAS

4/29/25 RKKE

Permenergosbyt reports for 2024 by IFRS

4/29/25 PMSB

Diasoft reported for 3 months of 2025 by RAS

4/29/25 DIAS

VseInstrument.ru will pay dividends until the end of 2025

4/29/25 VSEH

Rosseti North-West reported for 3 months of 2025 by RAS

4/29/25 MRKZ

Tattelecom reports for 2024 by IFRS

4/29/25 TTLK